Abstract P1-01-02: Circulating tumor cells (CTC) and endothelial cells (CEC) prognostic value in HER2 negative metastatic breast cancer patients treated with first line weekly paclitaxel and bevacizumab: First results of a prospective cohort from the French Breast Cancer InterGroup Unicancer (UCBG): COMET study
2020 ◽
2013 ◽
Vol 9
(1)
◽
pp. 29
◽
2019 ◽
2010 ◽
Vol 28
(15_suppl)
◽
pp. 1033-1033
◽